Literature DB >> 831965

Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking.

P A Emerson, P Marks.   

Abstract

A trial of low-dose subcutaneous heparin to prevent thromboembolic complications after myocardial infarction was carried out in 78 patients. Of the 37 heparin-treated patients only two (5%) developed evidence of leg vein thrombosis, while 14 (34%) of the 41 controls did so, and five controls developed pulmonary emboli. Leg vein thrombosis developed in 12 (50%) of the 24 controls who did not smoke cigarettes but in only two (13%) of the 17 controls who were cigarette smokers. Non-smokers who have a myocardial infarction should be given low-dose heparin subcutaneously to prevent leg vein thrombosis and pulmonary embolism.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 831965      PMCID: PMC1603609          DOI: 10.1136/bmj.1.6052.18

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  Letter: Smoking and deep vein thrombosis.

Authors:  R Doll
Journal:  Br Med J       Date:  1974-08-17

2.  Low-dose heparin after myocardial infarction.

Authors:  A J Handley
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

3.  Frequency of venous thrombosis after myocardial infarction.

Authors:  B J Maurer; R Wray; J P Shillingford
Journal:  Lancet       Date:  1971-12-25       Impact factor: 79.321

4.  125-I-labelled fibrinogen test adapted for routine screening for deep-vein thrombosis.

Authors:  V V Kakkar; A N Nicolaides; J T Renney; J R Friend; M B Clarke
Journal:  Lancet       Date:  1970-03-14       Impact factor: 79.321

5.  Increased incidence of deep vein thrombosis after myocardial infarction in non-smokers.

Authors:  P Marks; P A Emerson
Journal:  Br Med J       Date:  1974-07-27

6.  Coronary occlusion treated with small doses of heparin.

Authors:  K A Steffensen
Journal:  Acta Med Scand       Date:  1969-12

7.  Heparin in the prevention of deep vein thrombosis after myocardial infarction.

Authors:  A J Handley; P A Emerson; P R Fleming
Journal:  Br Med J       Date:  1972-05-20

8.  Influence of smoking on deep vein thrombosis after myocardial infarction.

Authors:  A J Handley; D Teather
Journal:  Br Med J       Date:  1974-07-27

9.  Myocardial infarction and deep-vein thrombosis.

Authors:  A N Nicolaides; V V Kakkar; J T Renney; P H Kidner; D C Hutchison; M B Clarke
Journal:  Br Med J       Date:  1971-02-20
  9 in total
  7 in total

Review 1.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

Review 2.  The venous thrombotic risk in nonsurgical patients.

Authors:  J Bouthier
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Medical management of acute myocardial infarction in Ireland: information from the Second International Study of Infarct Survival (ISIS-2).

Authors:  G A MacGowan; D O'Callaghan; J H Horgan
Journal:  Ir J Med Sci       Date:  1991-11       Impact factor: 1.568

4.  Thrombosis: its role and prevention in cardiovascular events-Part II.

Authors:  L A Harker; A R Thompson; J M Harlan
Journal:  West J Med       Date:  1981-04

5.  Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.

Authors:  R Collins; S MacMahon; M Flather; C Baigent; L Remvig; S Mortensen; P Appleby; J Godwin; S Yusuf; R Peto
Journal:  BMJ       Date:  1996-09-14

6.  Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC).

Authors:  C T Prince; D J Becker; T Costacou; R G Miller; T J Orchard
Journal:  Diabetologia       Date:  2007-09-02       Impact factor: 10.122

Review 7.  Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux.

Authors:  Marcello Di Nisio; Ettore Porreca
Journal:  Drug Des Devel Ther       Date:  2013-09-16       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.